Thus, in AML, integrin αvβ3 is able to enhance β-catenin activation through PI3K/AKT/GSK3β signaling and therefore constitutes an important prognostic marker, especially for patients with the FLT3-ITD mutation. Here, AKT1 is linked to acute myeloid leukemia.